Who are nicotine acid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nicotinic acid (niacin), Statin plus niacin ER/laropiprant, Niacin Extended Release/Lovastatin, Niacin plus laropiprant, Slo-Niacin, atorvastatin, nicotinic acid/laropiprant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicotine-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

nicotine acid — Competitive Intelligence Brief

nicotine acid (nicotine acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: lipid-regulating agent. Area: Cardiovascular.

phase 3 lipid-regulating agent GPR109A Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

nicotine acid (nicotine acid) — GWT-TUD GmbH. Nicotine acid, also known as niacin, primarily functions by reducing the production of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol in the liver.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
nicotine acid TARGET	nicotine acid	GWT-TUD GmbH	phase 3	lipid-regulating agent	GPR109A
Nicotinic acid (niacin)	Nicotinic acid (niacin)	Charite University, Berlin, Germany	marketed	Lipid-modifying agent; B vitamin	GPR109A (HM74A receptor)
Statin plus niacin ER/laropiprant	Statin plus niacin ER/laropiprant	University of Ioannina	marketed	Statin combined with niacin ER and DP1 antagonist	HMG-CoA reductase (statin component); GPR109A/PUMA-G (niacin component); DP1 receptor (laropiprant component)
Niacin Extended Release/Lovastatin	Niacin Extended Release/Lovastatin	In His Image	marketed	Statin/Niacin combination; Lipid-modifying agent	HMG-CoA reductase (lovastatin); GPR109A/PUMA-G receptor (niacin)
Niacin plus laropiprant	Niacin plus laropiprant	Institut Investigacio Sanitaria Pere Virgili	marketed	Lipid-modifying agent combination	DP1 receptor (laropiprant component); niacin acts on GPR109A and other pathways
Slo-Niacin, atorvastatin	Slo-Niacin, atorvastatin	University of Washington	marketed	Niacin derivative and HMG-CoA reductase inhibitor (statin combination)	Nicotinic acid receptor (GPR109A) and HMG-CoA reductase
nicotinic acid/laropiprant	nicotinic acid/laropiprant	Manchester University NHS Foundation Trust	marketed	Lipid-modifying agent / Antilipemic	GPR109A receptor (laropiprant component); nicotinic acid acts on multiple lipid metabolism pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (lipid-regulating agent class)

GWT-TUD GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nicotine acid — Competitive Intelligence Brief. https://druglandscape.com/ci/nicotine-acid. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab